NCT07403552 Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
| NCT ID | NCT07403552 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Ensho Therapeutics, Inc. |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-01-31 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2026-01-31 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Eligibility Criteria
Inclusion Criteria: * Participants (males and females) at least 18 years of age * Ability to provide written informed consent * In good heath as determined by medical evaluation, * Willing and able to comply with trial restrictions, procedures, and requirements Exclusion Criteria: * Known sensitivity to any components of the IMP * History of relevant drug hypersensitivity * Presents or has a history of clinically significant diseases * History of difficulty swallowing tablets or capsules. * Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07403552 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07403552 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07403552 currently recruiting?
Yes, NCT07403552 is actively recruiting participants. Contact the research team at operations@enshorx.com for enrollment information.
Where is the NCT07403552 trial being conducted?
This trial is being conducted at Anaheim, United States.
Who is sponsoring the NCT07403552 clinical trial?
NCT07403552 is sponsored by Ensho Therapeutics, Inc.. The trial plans to enroll 24 participants.